# Bioavailability Study of Magne-B6 New Formulation

> **NCT06386211** · PHASE1 · COMPLETED · sponsor: **Opella Healthcare Group SAS, a Sanofi Company** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MAGNE-B6 Oral Solution
- **DRUG:** MAGNE-B6 New Formulation Tablet

## Key facts

- **NCT ID:** NCT06386211
- **Lead sponsor:** Opella Healthcare Group SAS, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-03
- **Primary completion:** 2024-08-24
- **Final completion:** 2024-08-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06386211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06386211, "Bioavailability Study of Magne-B6 New Formulation". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06386211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*